Everything you mention is true and well known, but past history now. They are not, IMO, ongoing corporate health issues.
As LeeKing said, aside from the value of the IP/technology to the company and its own proprietary products, the licensing potential off the back of the successful trial and patent issue should open up multiple opportunities. Craig has always said as much.
Said it before, but there must be, and probably are, several majors keeping a very close eye on CDX. The FDA-cleared IP is globally unique, commercially applicable, and you would imagine, highly desirable. If CDX has not yet quite turned the corner, developments like this will be part of what they are looking for to verify they are in the process of doing so.
As always, execution is key. First survival then growth. With the recent financing, in essence a private PE play, Craig and Niall have proven they are not quitters and back themselves to get the job done.
CDX Price at posting:
8.0¢ Sentiment: Buy Disclosure: Held
